# EDGAR Filing Document

**Accession Number:** 0001404281
**File Stem:** 0000000000-26-004691
**Filing Date:** 2026-5
**Character Count:** 2431
**Document Hash:** 94fc1f438c991e720699467d46e2acd9
**Contains OCR:** False
**Source Format:** 

## Filing Content

## Filing Summary
**0000000000-26-004691.hdr.sgml**: 20260609

**ACCESSION NUMBER**: 0000000000-26-004691

**CONFORMED SUBMISSION TYPE**: UPLOAD

**PUBLIC DOCUMENT COUNT**: 2

**FILED AS OF DATE**: 20260507

**FILED FOR**: 

**COMPANY DATA:**
- **COMPANY CONFORMED NAME:** Eledon Pharmaceuticals, Inc.
- **CENTRAL INDEX KEY:** 0001404281
- **STANDARD INDUSTRIAL CLASSIFICATION:** PHARMACEUTICAL PREPARATIONS [2834]
- **ORGANIZATION NAME:** 03 Life Sciences
- **EIN:** 000000000
- **STATE OF INCORPORATION:** DE
- **FISCAL YEAR END:** 1231

**FILING VALUES:**
- **FORM TYPE:** UPLOAD
- **SEC FILE NUMBER:** 333-295498

**BUSINESS ADDRESS:**
- **STREET 1:** 19800 MACARTHUR BLVD.
- **STREET 2:** SUITE 250
- **CITY:** IRVINE
- **STATE:** CA
- **ZIP:** 92612
- **BUSINESS PHONE:** 949-238-8090

**MAIL ADDRESS:**
- **STREET 1:** 19800 MACARTHUR BLVD.
- **STREET 2:** SUITE 250
- **CITY:** IRVINE
- **STATE:** CA
- **ZIP:** 92612

**FORMER COMPANY:**
- **FORMER CONFORMED NAME:** Novus Therapeutics, Inc.
- **DATE OF NAME CHANGE:** 20170511

**FORMER COMPANY:**
- **FORMER CONFORMED NAME:** Tokai Pharmaceuticals Inc
- **DATE OF NAME CHANGE:** 20070622
**PUBLIC REFERENCE ACCESSION NUMBER**: 0001193125-26-201426

## Text-Extract

```

                                                           May 7, 2026

David-Alexandre Gros
Chief Executive Officer
Eledon Pharmaceuticals, Inc.
19800 MacArthur Blvd., Suite 250
Irvine, CA 92612

       Re: Eledon Pharmaceuticals, Inc.
           Registration Statement on Form S-3
           Filed May 1, 2026
           File No. 333-295498
Dear David-Alexandre Gros:

       This is to advise you that we have not reviewed and will not review your
registration
statement.

        Please refer to Rules 460 and 461 regarding requests for acceleration.
We remind you
that the company and its management are responsible for the accuracy and
adequacy of their
disclosures, notwithstanding any review, comments, action or absence of action
by the staff.

       Please contact Lauren Hamill at 303-844-1008 with any questions.

                                                           Sincerely,

                                                           Division of
Corporation Finance
                                                           Office of Life
Sciences
cc:    Shelly Heyduk

```

### Attached PDF Documents

**Attachment 1:** `filename1`

_No text found in this document._